NCT05905887 2026-04-07
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
Clinical Trials
28 trialsNCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
NCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT04072042 2025-05-14
BIOVAS
Ruijin Hospital
Phase 2 Recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT04824352 2024-05-14
AIEO
Peking University People's Hospital
Phase 2 Suspended
NCT03711279 2024-02-29
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT06140732 2023-11-20
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
Xuanwu Hospital, Beijing
Phase 2 Unknown
NCT06125171 2023-11-09
Tucidinostat Plus Apatinib for Advanced Osteosarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03742193 2023-11-01
PROACH
Ruijin Hospital
Phase 2 Unknown
NCT04074564 2023-10-23
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
HRYZ Biotech Co.
Phase EARLY_PHASE1 Unknown
NCT05751733 2023-03-02
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Xiangya Hospital of Central South University
Phase NA Recruiting
NCT04012827 2022-09-07
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT04690231 2022-03-15
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Peking University People's Hospital
Phase NA Completed
NCT05265793 2022-03-04
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Fudan University
Phase 2 Unknown
NCT04260113 2021-01-05
AIAC
Peking University People's Hospital
Phase NA Completed
NCT04447274 2020-06-25
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
ChineseAMS
Phase 2 Unknown
NCT03104335 2020-05-19
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
Phase 2 Withdrawn
NCT03359018 2020-05-19
APFAO
Peking University People's Hospital
Phase 2 Completed
NCT04351308 2020-05-19
MAPAC
Peking University People's Hospital
Phase 2 Unknown
NCT04239443 2020-01-27
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
Hunan Cancer Hospital
Phase 2 Unknown
NCT04126811 2019-10-15
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04126993 2019-10-15
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03539172 2018-05-30
RASS
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT02711007 2018-04-23
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Peking University People's Hospital
Phase 2/3 Completed
NCT03163381 2017-05-23
Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
Henan Cancer Hospital
Phase 2 Unknown
NCT03121846 2017-05-22
Mesylate Apatinib for Stage â…£ STS After Failure of Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03064243 2017-02-27
A Phase II Study of Apatinib in STS Patients
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 2 Unknown